tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Andreas Argyrides, 114 are a BUY (85.07%), 19 are a HOLD (14.18%), 1 are a SELL (0.75%).
Analyst Andreas Argyrides, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 37.21% that have a potential upside of 44.31% achieved within 156 days.
Andreas Argyrides’s has documented 261 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on IFRX, InflaRx N.V. at 24-Apr-2026.
Analyst best performing recommendations are on MNPR (MONOPAR THERAPEUTICS).
The best stock recommendation documented was for MNPR (MONOPAR THERAPEUTICS) at 9/3/2025. The price target of $77 was fulfilled within 22 days with a profit of $40.79 (112.65%) receiving and performance score of 51.2.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 11-Mar-2024
$23
$12.23 (113.56%)
$26
Buy Since 22-Nov-2017
$12
$1.23 (11.42%)
$12
Buy Since 02-Jun-2023
$32
$21.52 (205.34%)
$39
Buy Since 15-Dec-2025
$18
$7.52 (71.76%)
$20
Buy Since 15-Nov-2024
$17
$6.52 (62.21%)
$18
Which stock is Andreas Argyrides is most bullish on?
Which stock is Andreas Argyrides is most reserved on?
What Year was the first public recommendation made by Andreas Argyrides?
